New medicines for tuberculosis

Project Information

NM4TB

Grant agreement ID: 18923

Start date 1 January 2006

End date 30 June 2011

Funded under

• Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006.

Total cost € 12 879 968,00

EU contribution € 11 070 000,00

Coordinated by

ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE
Switzerland

Objective

The explicit aim of the NM4TB project is to successfully develop new drugs for the treatment of tuberculosis (TB) with the following desired properties: * High potency to reduce treatment duration, * Activity against persistent bacilli, * Inhibition of ne w target classes, * Activity against multidrug resistant TB, * Specificity for Mycobacterium tuberculosis. This will be achieved through an integrated approach implemented by a team that combines some of Europe's leading academic TB researchers with a maj or pharmaceutical company and three SMEs with a strong commitment to discovering new anti-infective agents. Four interlinked, cutting-edge work packages (WP1) have been assembled: * WP1 provides all of the enabling technologies expected of a modern drug development programme, * WP2 is devoted to validation of an attractive range of targets, * WP3 generates three dimensional structures of targets with their inhibitors, * WP4 provides an exhaustive approach to screening and lead optimization culminating in candidate drugs. NM4TB has a comprehensive portfolio of potential and validated targets plus several novel, proprietary anti-TB agents in its drug development pipeline. Among the validated targets are several enzymes involved in highly druggable areas su ch as cell wall biogenesis, nucleic acid synthesis and central metabolic pathways for which assays amenable to high-throughput screening are available. Intensive efforts will focus on rapidly emerging targets that impact upon two as-yet untouched areas of the physiology of M. tuberculosis signal transduction pathways and persistence.

Fields of science

• medical and health sciences › basic medicine › pharmacology and pharmacy › drug discovery
• natural sciences › biological sciences › biochemistry › biomolecules › nucleic acids
• medical and health sciences › clinical medicine › pneumology › tuberculosis
• medical and health sciences › basic medicine › physiology
• medical and health sciences › basic medicine › pharmacology and pharmacy › drug resistance › multidrug resistance

Programme(s)

• FP6-LIFESCIHEALTH - Life sciences, genomics and biotechnology for health: Thematic Priority 1 under the Focusing and Integrating Community Research programme 2002-2006.

Topic(s)

• LSH-2004-2.3.0-4 - Development of new drugs for the treatment of tuberculosis

Call for proposal

FP6-2004-LIFESCIHEALTH-5
See other projects for this call

Funding Scheme

IP - Integrated Project

Coordinator

ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE

• EU contribution: No data
• Address: Batiment CE 3.316 Station 1 ; LAUSANNE ; Switzerland
• Total cost: No data

Participants (21)

UPPSALA UNIVERSITET

Sweden

• EU contribution: No data
• Address: Sankt Olofsgatan 10 B ; UPPSALA
• Total cost: No data

ASTRAZENECA

United Kingdom

• EU contribution: No data
• Address: Mereside, Alderley Park ; MACCLESFIELD
• Total cost: No data

QUEEN MARY & WESTFIELD COLLEGE

United Kingdom

• EU contribution: No data
• Address: 43 Rutland House, New Road ; LONDON
• Total cost: No data

INSTITUT PASTEUR

France

• EU contribution: No data
• Address: 25-28 rue du Dr Roux ; PARIS
• Total cost: No data

UNIVERSITÀ DEGLI STUDI DI PAVIA

Italy

• EU contribution: No data
• Address: Strada Nuova, 65 ; PAVIA
• Total cost: No data

STATENS SERUM INSTITUT

Denmark

• EU contribution: No data
• Address: Artillerivej 5 ; COPENHAGEN S
• Total cost: No data

LEIBNIZ INSTITUT FUR NATURSTOFF-FORSCHUNG UND INFEKTIONSBIOLOGIE E.V.HANS-KNÖLL-INSTITUT

Germany

• EU contribution: No data
• Address: Beutenbergstrasse 11a ; JENA
• Total cost: No data

UNIVERSITY OF MANCHESTER

United Kingdom

• EU contribution: No data
• Address: Oxford Road ; MANCHESTER
• Total cost: No data

COMENIUS UNIVERSITY, FACULTY OF NATURAL SCIENCES

Slovakia

• EU contribution: No data
• Address: Mlynska dolina ; BRATISLAVA
• Total cost: No data

UNIVERSITY OF ZURICH

Switzerland

• EU contribution: No data
• Address: Raemistr. 71 ; ZURICH
• Total cost: No data

VICHEM CHEMIE RESEARCH LTD.

Hungary

• EU contribution: No data
• Address: Herman Ottó u. 15 ; BUDAPEST
• Total cost: No data

ASTEX THERAPEUTICS LIMITED

United Kingdom

• EU contribution: No data
• Address: 436 Cambridge Science Park, Milton Road ; CAMBRIDGE
• Total cost: No data

NEED PHARMACEUTICALS

Italy

• EU contribution: No data
• Address: Via Ariberto 17 ; MILANO
• Total cost: No data

ST GEORGE'S HOSPITAL MEDICAL SCHOOL

United Kingdom

• EU contribution: No data
• Address: Cranmer Terrace ; LONDON
• Total cost: No data

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE

France

• EU contribution: No data
• Address: Rue Michel-Ange, 3 ; PARIS
• Total cost: No data

A.N. BAKH INSTITUTE OF BIOCHEMISTRY OF THE RUSSIAN ACADEMY OF SCIENCES

Russia

• EU contribution: No data
• Address: Leninsky prospect, 33 ;
• Total cost: No data

COUNCIL FOR SCIENTIFIC AND INDUSTRIAL RESEARCH

South Africa

• EU contribution: No data
• Address: Meiring Naudé Street ; 395
• Total cost: No data

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

• EU contribution: No data
• Address: Trinity Lane, The Old Schools ; CAMBRIDGE
• Total cost: No data

ASTRA ZENECA INDIA PVT LTD

India

• EU contribution: No data
• Address: 'Avishkar',Bellary Road,Hebbal, ; BANGALORE
• Total cost: No data

UNIVERSIDAD DEL PAÍS VASCO/EUSKAL HERRIKO UNIBERTSITATEA

Spain

• EU contribution: No data
• Address: Bª SARRIENA S/N ; LEIOA
• Total cost: No data

SCIPROM SARL

Switzerland

• EU contribution: No data
• Address: Rue du Centre 70 ; ST-SULPICE
• Total cost: No data